Mostrar o rexistro simple do ítem

dc.contributor.authorHeumann, P.*
dc.contributor.authorAguado-Barrera, M.E.*
dc.contributor.authorAvuzzi, B.*
dc.contributor.authorAzria, D.*
dc.contributor.authorBriers, E.*
dc.contributor.authorBultijnck, R.*
dc.contributor.authorChoudhury, A.*
dc.contributor.authorDe Ruysscher, D.*
dc.contributor.authorFarcy-Jacquet, M.-P.*
dc.contributor.authorFonteyne, V.*
dc.contributor.authorGómez Caamaño, Antonio *
dc.contributor.authorHelmbold, I.*
dc.contributor.authorJohnson, K.*
dc.contributor.authorKerns, S.L.*
dc.contributor.authorLambrecht, M.*
dc.contributor.authorLingard, Z.*
dc.contributor.authorRancati, T.*
dc.contributor.authorRosenstein, B.S.*
dc.contributor.authorSperk, E.*
dc.contributor.authorPaul Symonds, R.*
dc.contributor.authorTalbot, C.*
dc.contributor.authorValdagni, R.*
dc.contributor.authorVega Gliemmo, Ana*
dc.contributor.authorVeldeman, L.*
dc.contributor.authorWard, T.*
dc.contributor.authorWebb, A.*
dc.contributor.authorWest, C.M.*
dc.contributor.authorChang-Claude, J.*
dc.contributor.authorSeibold, P.*
dc.date.accessioned2025-09-08T12:18:17Z
dc.date.available2025-09-08T12:18:17Z
dc.date.issued2023
dc.identifier.citationHeumann P, Aguado-Barrera ME, Avuzzi B, Azria D, Briers E, Bultijnck R, et al. Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study. Radiotherapy and Oncology. 2023;178.
dc.identifier.issn1879-0887
dc.identifier.otherhttps://portalcientifico.sergas.gal//documentos/63cc8c97ab05b07b66656766
dc.identifier.urihttp://hdl.handle.net/20.500.11940/21250
dc.description.abstractIntroduction: Previous studies showed that healthcare professionals and patients had only moderate to low agreement on their assessment of treatment-related symptoms. We aimed to determine the levels of agreement in a large cohort of prostate cancer patients. Methods: Analyses were made of data from 1,756 prostate cancer patients treated with external beam radiotherapy (RT) and/or brachytherapy in Europe and the USA and recruited into the prospective multicentre observational REQUITE study. Eleven pelvic symptoms at the end of RT were compared after translating patient-reported outcomes (PROs) into CTCAE-based healthcare professional ratings. Gwet's AC2 agreement coefficient and 95% confidence intervals were calculated for each symptom. To compare severity of grading between patients and healthcare professionals, percent agreement and deviations for each symptom were graphically depicted. Stratified and sensitivity analyses were conducted to identify potential influencing factors and to assess heterogeneity and robustness of results. Results: The agreement for the 11 pelvic symptoms varied from very good (AC2 > 0.8: haematuria, rectal bleeding, management of sphincter control) to poor agreement (AC2 ? 0.2: proctitis and urinary urgency). Fatigue had a negative impact on the agreement. Patients tended to grade symptoms more severely than healthcare professionals. Information on sexual dysfunction was missing more frequently in healthcare professional assessment than PROs. Conclusion: Agreement was better for observable than subjective symptoms, with patients usually grading symptoms more severely than healthcare professionals. Our findings emphasize that PROs should complement symptom assessment by healthcare professionals and be taken into consideration for clinical decision-making to incorporate the patient perspective.
dc.languageeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshMale *
dc.subject.meshHumans *
dc.subject.meshProspective Studies *
dc.subject.meshProstatic Neoplasms *
dc.subject.meshRectum *
dc.subject.meshUrination Disorders *
dc.subject.meshDelivery of Health Care *
dc.titleComparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study
dc.typeArtigo
dc.authorsophosHeumann, P.; Aguado-Barrera, M.E.; Avuzzi, B.; Azria, D.; Briers, E.; Bultijnck, R.; Choudhury, A.; De Ruysscher, D.; Farcy-Jacquet, M.-P.; Fonteyne, V.; Gómez Caamaño, A.; Helmbold, I.; Johnson, K.; Kerns, S.L.; Lambrecht, M.; Lingard, Z.; Rancati, T.; Rosenstein, B.S.; Sperk, E.; Paul Symonds, R.; Talbot, C.; Valdagni, R.; Vega, A.; Veldeman, L.; Ward, T.; Webb, A.; West, C.M.; Chang-Claude, J.; Seibold, P.
dc.identifier.doi10.1016/j.radonc.2022.11.015
dc.identifier.sophos63cc8c97ab05b07b66656766
dc.journal.titleRadiotherapy and Oncology*
dc.organizationConsellería de Sanidade
dc.organizationFundación Pública Galega de Medicina Xenómica
dc.relation.publisherversionhttps://doi.org/10.1016/j.radonc.2022.11.015
dc.rights.accessRightsopenAccess*
dc.subject.keywordConsellería Sanidade
dc.subject.keywordFPGMX
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number178


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAttribution-NonCommercial-NoDerivatives 4.0 International